logo
This company sends human remains to space for cosmic memorials. Many launch from Florida

This company sends human remains to space for cosmic memorials. Many launch from Florida

Yahoo11 hours ago

Since the dawn of humanity, we humans have found countless ways to honor our dead.
From traditional burials to the scattering of one's ashes at sea, the methods for the deceased to be honored are as varied as the cultures that comprise our world.
But what about those who prefer to be memorialized on a more cosmic scale? Well, it turns out they have that option, too.
For about three decades, a company based in Texas has billed itself as the first and most prominent business to offer what's referred to as "space burials." Celestis, which recently conducted a mission from California, offers services that involve sending cremated remains or human DNA beyond Earth's atmosphere.
Often, familiar faces and well-known public figures − from "Star Trek" cast members to U.S. presidents − have had their remains flown to orbit as part of a celestial burial or memorial.
Many of Celestis' memorial spaceflights have launched from Cape Canaveral Space Force Base and NASA's Kennedy Space Center in Florida. Here's what to know about Celestis and its memorial spaceflights.
Celestis is a company based in Houston, Texas, specializing in transporting human remains to space for cosmic memorials.
Capsules containing DNA and human remains are included as payloads on spacecraft launched into orbit by other companies, including SpaceX and United Launch Alliance.
Celestis' services allow for families to pay for cremated remains in capsules or DNA to be launched into space, where they can either return intact or remain until they reenter Earth's atmosphere, "harmlessly vaporizing like a shooting star in final tribute," the company says on its website. In another offering, the company facilitates the transportation of memorial capsules to interplanetary space well beyond the moon.
Celestis' most recent payload of memorial capsules was included in a SpaceX rideshare mission known as Transporter 14. The mission got off the ground Monday, June 23, from Vandenberg Space Force Base in California.
A total of 166 individual Celestis memorial capsules were on board a Nyx spacecraft manufactured by Europe-based The Exploration Company (TEC,) which hitched a ride on SpaceX's famous Falcon 9 rocket.
The payload of memorial capsules was part of about 70 total payloads, including small satellites, that the Falcon 9 helped to deliver for paying customers to a sun-synchronous orbit, meaning they matched Earth's rotation around the sun.
The launch was meant to be Celestis' first-ever to return from an altitude high enough to be considered Earth's orbit.
The Nyx module reached low-Earth orbit, where it traveled for three hours at about 17,000 miles per hour and completed two full orbits around Earth.
But instead of safely reentering Earth's atmosphere to land in the Pacific Ocean as planned, the Nyx spacecraft's parachute failed and it crashed into the sea, losing the capsules.
If you want to send your deceased loved one on a final cosmic journey, the cost to do so isn't that much different from the price of the average typical funeral or burial service.
The cheapest option of sending memorial capsules to space and back, known as "Earth rise," starts at $3,495. The price to send a loved one's remains all the way up to orbit starts at $4,995.
After that, though, the costs for Celestis' services start to climb.
Both the company's lunar burial and interplanetary services start at $12,995, according to its website.
The recent mission was Celestis' 25th overall since it was founded in 1994.
The company's maiden voyage took place in April 1997, when a Pegasus rocket carrying the remains of 24 people, including "Star Trek" creator Gene Roddenberry, launched over the Spanish Canary Islands. The flight capsules on board a Celestis spacecraft then reentered Earth's atmosphere about a month later.
Celestis' first and only successful lunar burial mission to date then occurred a year later in January 1998 from what was then still called the Cape Canaveral Air Force Station in Florida. Conducted at NASA's request, the mission included a capsule on board the agency's Lunar Prospector containing the ashes of geologist Eugene Shoemaker.
Celestis has no more missions planned for 2025, according to its website.
The next flight, planned for early 2026, appears to be an orbital mission launching from Cape Canaveral Space Force Base. Reservations are open until Aug. 1, 2025.
Celestis previously made headlines in January 2024 when its plans to land human remains on the moon's surface attracted some controversy.
The plan was for the remains and DNA of more than 70 deceased people to be included on a lunar lander bound for the moon. That included – once again – remains from 'Star Trek' creator Gene Roddenberry, as well as science fiction writer Arthur C. Clarke.
But Navajo Nation, the largest tribe of Native Americans in the United States, vehemently opposed the lunar burial, penning a letter decrying the plans as "a profound desecration."
Ultimately, though, the remains never made it to the moon's surface anyway. Pittsburgh-based aerospace company Astrobotic's Peregrine lander fell short of its destination when it began leaking a "critical" amount of propellant – instead burning up in Earth's atmosphere after launch.
Roddenberry and Clarke, best known for authoring "2001: A Space Odyssey" that inspired Stanley Kubrick's film of the same name, are not the only well-known people whose remains have flown to outer space on a Celestis mission.
Among the notable names to have been included are several actors from the original "Star Trek" series and NASA astronauts.
Here's a list Celestis provided to the USA TODAY Network:
James Doohan, who portrayed Scotty in the original "Star Trek" series (remember the phrase, "Beam me up, Scotty"?)
Nichelle Nichols, the first Black woman featured in a major television series who portrayed Nyota Uhura in "Star Trek"
DeForest Kelley, who portrayed Dr. Leonard "Bones" McCoy in the original "Star Trek" series
Three American presidents, George Washington, Dwight D. Eisenhower and John F. Kennedy, whose DNA in the form of hair samples was included on past flights
Several NASA astronauts, including L. Gordon Cooper, one of the original Mercury 7 astronauts, and NASA's first Australian-American Astronaut, Philip K. Chapman
Eric Lagatta is the Space Connect reporter for the USA TODAY Network. Reach him at elagatta@gannett.com
This article originally appeared on Florida Today: You can send a loved one's remains to space: Cosmic memorials, explained

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New Data at EULAR Signal Advances in RA, Myopathy, Gout
New Data at EULAR Signal Advances in RA, Myopathy, Gout

Medscape

time32 minutes ago

  • Medscape

New Data at EULAR Signal Advances in RA, Myopathy, Gout

Barcelona has become the world capital of rheumatology by hosting the 2025 Annual Meeting of the European Alliance of Associations for Rheumatology (EULAR) in Spain. 'This is the world's largest rheumatology event,' said Daniel Aletaha, MD, president of EULAR and head of the Department of Rheumatology at the University Clinic for Internal Medicine III, MedUni Vienna, Vienna, Austria, during the conference opening session. He highlighted the scale of participation: 5125 abstracts submitted from 95 countries, 117 sessions, and 350 speakers from 45 nations. Inflammatory and Autoimmune Disease Among the plenary highlights was research led by Jason D. Turner, PhD, a postdoctoral research fellow at the University of Birmingham, Birmingham, England. His comparative analysis of synovial tissue using single-cell and spatial transcriptomics identified overlapping disease pathways in spontaneous inflammatory arthritis and arthritis induced by immune checkpoint inhibitors. 'We found that the synovium in checkpoint inhibitor-associated arthritis is enriched with fibroblasts and T cells, is highly vascularised, and contains large numbers of CXCL9/10/11+ macrophages and CD8+ T cells. These findings support the current use of tumour necrosis factor inhibitors for this condition, although further investigation is needed to understand their applicability to spontaneous arthritis,' Turner explained. Hector Chinoy, PhD, FRCP, professor of rheumatology at the University of Manchester and lead at the Salford Royal Adult Neuromuscular Service, Manchester, England, presented the results of the ALKIVIA phase 2 study. This trial evaluated the efficacy of subcutaneous efgartigimod (PH20) administration in adults with active idiopathic inflammatory myopathy. The drug led to significant improvements in the Total Improvement Score compared with placebo and showed good tolerability and safety. 'These findings demonstrate the mechanistic importance of neonatal Fc receptor inhibition and suggest a potential pathogenic role for autoantibodies. These findings support the continued evaluation of the drug in the ongoing phase 3 trial' Chinoy said. Scleroderma, Preclinical Rheumatoid Arthritis (RA), Gout, and Lupus Adela‑Cristina Sarbu, MD, a researcher specialising in systemic sclerosis and interstitial lung disease at the University Hospital Bern, Bern, European Scleroderma Trials and Research group (EUSTAR), and the University of Zurich, Zurich, Switzerland, presented the findings from the EUSTAR cohort. In conclusion, exposure to prostanoids appeared to be associated with a slower progression of interstitial lung disease in patients with mild vascular disease. In contrast, exposure to endothelin receptor antagonists appeared to be beneficial in preventing symptom worsening in patients with more severe vascular diseases. 'No independent mortality benefit was seen with vasoactive or vasodilator drugs. Their effectiveness seems to depend on the severity of vascular disease' Sarbu noted, calling for further long-term studies. The ALTO study, an extension of the APIPPRA trial, led by Andrew Cope, PhD, of King's College London, London, England, found that a 1-year course of abatacept in individuals at high risk of developing RA could delay disease onset by up to 4 years. 'Individuals with baseline autoantibody profiles are more likely to develop the disease and respond well to T-cell co-stimulation blockade. Abatacept reduces the symptom burden during treatment but does not provide sustained benefits after treatment discontinuation. No new safety concerns were reported,' according to Cope. Edoardo Cipolletta, MD, rheumatologist at the Marche University Hospital, Ancona, Italy, and research associate at the University of Nottingham, Nottingham, England, presented an analysis of data on primary care, hospitalization, and mortality outcomes related to gout, based on cohorts from the UK and Sweden. The study found that achieving serum urate levels below 360 µmol/L within a year of initiating urate-lowering treatment was associated with a significantly lower risk for major adverse cardiovascular events. The 5-year relative risk reduction ranged from 6% to 11%, with an absolute survival benefit of 1.3%-1.4%. 'The association was consistent regardless of prior cardiovascular disease and across all sensitivity analyses,' Cipolletta reported. Richard A. Furie, MD, chief of Rheumatology at Northwell Health in New York, presented results from the REGENCY study, which evaluated obinutuzumab in patients with lupus nephritis. Award Recognition Miriam Ruiz Ponce, MSc, a predoctoral researcher at the Maimonides Biomedical Research Institute in Córdoba, Spain received one of the EULAR award for translational basic science. She developed a mouse model of fatty liver disease associated with inflammatory arthritis to evaluate the anti-inflammatory and metabolic properties of apremilast, a drug commonly used in psoriatic arthritis. 'Early results have shown that the drug has promising effects, as it partially reverses liver damage, as well as inflammation. These are the initial results, but it could be a potential treatment for inflammation and for the deleterious effects on the liver in these patients. It is an honour to receive this award, which motivates us to continue our research under the leadership of my mentor, Nuria Barbarroja Puerto, PhD, the principal investigator of the potential treatment targeting inflammation and liver damage,' she said. Chinoy disclosed financial relationships with AstraZeneca, Pfizer, PTC Therapeutics, and UCB. Furie disclosed the financial relationships with GSK and Genentech; the REGENCY study was funded by F. Hoffmann-La Roche. Sarbu and Cope disclosed having no relevant financial relationships. Turner, Cipolletta, and Ponce did not provide conflict-of-interest disclosures.

Hydroxychloroquine May Tame Preeclampsia in Lupus Patients
Hydroxychloroquine May Tame Preeclampsia in Lupus Patients

Medscape

time4 hours ago

  • Medscape

Hydroxychloroquine May Tame Preeclampsia in Lupus Patients

Use of hydroxychloroquine during pregnancy in patients with systemic lupus erythematosus (SLE) is associated with a reduced risk for preeclampsia, according to a recent nationwide cohort study. A population-based analysis from Sweden found that women with SLE taking hydroxychloroquine had about half the risk for preeclampsia compared with those not taking it, but there was no clear association between hydroxychloroquine use and preterm birth risk. 'These findings suggest possibly favorable, or at least not harmful, associations between hydroxychloroquine and preeclampsia and preterm delivery in pregnancies in women with SLE, supporting the current recommendations for hydroxychloroquine treatment during pregnancy in these patients,' wrote Ngoc V. Nguyen, MPH, a PhD candidate at the Karolinska Institutet in Stockholm, Sweden, and his colleagues in The Lancet Rheumatology . '[Hydroxychloroquine] may actually reduce the risk of preeclampsia,' Nguyen told Medscape Medical News . Joshua Copel, MD, a professor of obstetricis, gynecology, and reproductive sciences and of pediatrics at Yale School of Medicine, New Haven, Connecticut, told Medscape Medical News the findings show that 'hydroxychloroquine certainly doesn't seem to cause an increased risk for spontaneous preterm birth, and it probably reduces the risk for preeclampsia or at least delays the onset of preeclampsia.' The researchers used the Swedish Medical Birth Register to identify all 959 singleton pregnancies among 685 women with SLE in Sweden between January 2007 and December 2022. Using the Prescribed Drug Register, they determined which patients had received at least two dispensations between 3 months before pregnancy through the end of the first trimester. Among the 42% of pregnancies that were nulliparous, 43% were exposed to hydroxychloroquine and 57% were unexposed. Among the other 58% of pregnancies that were parous, 40% were exposed and 60% were unexposed. Patients had an average age of 32 years and an average first-trimester BMI ranging from 23.7 to 24.9 across the different groups. They had been diagnosed with lupus for 5.4-6.8 years, and rates of prior miscarriages ranged from 19% to 38% across the groups. Preeclampsia occurred in 11% of exposed and 13% of unexposed nulliparous pregnancies and in 5% of exposed and 6% of unexposed parous pregnancies. Preterm birth occurred in 19% of exposed and 15% of unexposed nulliparous pregnancies and in 12% of exposed and 12% of unexposed parous pregnancies. After adjustment for confounders, these numbers translated to an overall 49% reduced risk for preeclampsia in those exposed to hydroxychloroquine (95% CI, 0.31-0.79; P = .003). Stratified by parity, however, the 59% preeclampsia risk reduction in nulliparous pregnancies exceeded the threshold for statistical significance (95% CI, 0.33-1.08; P = .085). The 44% reduction in parous pregnancies was significant (95% CI, 0.22-0.89; P = .02). Questions Remain Though these findings 'add to a growing body of evidence suggesting hydroxychloroquine may help lower the risk of preeclampsia,' Nguyen told Medscape Medical News , 'it's worth noting that not all studies have shown statistically significant effects [potentially because of] how hydroxychloroquine use was defined, how well patients adhered to it, or whether key factors like BMI and smoking were accounted for.' Alfred Kim, MD, PhD, an associate professor of rheumatology at Washington University Medicine in St. Louis, told Medscape Medical News that hydroxychloroquine 'has a well-established antithrombotic property,' as seen with antiphospholipid syndrome, and 'preeclampsia is a prothrombotic condition due to substantial endothelial dysfunction, driving complement and coagulation cascade activation.' 'It is not completely clear how hydroxychloroquine attenuates thrombosis, though,' Kim said. 'There are nice data suggesting that hydroxychloroquine inhibits platelet activation and thrombus formation, both of which can promote a preeclamptic state.' Other possibilities, Nguyen added, include antioxidant activity, improved placental perfusion, and stabilization of endothelial function, any of which could also, in theory, reduce the risk for preterm birth in certain cases. However, this study found no association with preterm birth overall (risk ratio [RR], 0.95; 95% CI, 0.67-1.34; P = .76), in nulliparous births (RR, 1.1; P = .69), or in parous births (RR, 0.75; P = .28). Adherence Barriers Present Challenges Grégoire Martin de Frémont, Gaëlle Guettrot-Imbert, and Nathalie Costedoat-Chalumeau of Paris City University in Paris wrote in an accompanying editorial in The Lancet Rheumatology that 'by suggesting a beneficial effect on preeclampsia, the rigorous and valuable findings reported by the authors provide an additional rationale for the use of hydroxychloroquine in all pregnant women with SLE, as currently recommended.' They add, however, that 'obstacles to its optimal use persist, including drug unavailability, lack of prescription, and, in many cases, patients' reluctance to take it.' Kim agreed that many barriers remain to hydroxychloroquine adherence during pregnancy. 'Sometimes it's due to the patient not fulfilling the prescription, whether this is due to cost — which is typically not an issue with hydroxychloroquine — to inadequate comprehension due to low literacy, cognitive issues, language or visual barriers to a lack of trust in the medication or the medical team prescribing hydroxychloroquine,' Kim said. Nguyen agreed that the challenge of adherence is complex, with hurdles that include misinformation about safety, mixed messages from providers, and challenges such as age, disease severity, or pill burden. 'Our study might help chip away at some of these barriers by offering strong evidence for benefit, not just safety. If we can reframe hydroxychloroquine as something that's protective during pregnancy — not just 'safe enough' — that might help patients feel more comfortable and providers more proactive,' he said. The research was funded by the US National Institutes of Health and the Ingegerd Johansson Donation. The authors reported no disclosures. Costedoat-Chalumeau reported grants from UCB and Roche and honoraria from Bristol Myers Squibb. Copel serves on the advisory board for Janssen Pharmaceuticals, Nuvo, SimHawk, and Pulsenmore; receives royalties from Elsevier and UpToDate; and owns a company that manufactures prenatal vitamins. Kim receives royalties from Kypha Inc.; sponsored research agreements with AstraZeneca, Bristol Myers Squibb, CRISPR Therapeutics, and Novartis; and has done consulting or speaking for AbbVie, Amgen, Atara Biotherapeutics, Aurinia Pharmaceuticals, Cargo Tx, Exagen Diagnostics, GlaxoSmithKline, Genentech/Roche, Hinge Bio, Invivyd, Johnson & Johnson, UpToDate, and Zenas BioPharma.

Diminishing Returns With Broader Use of ADHD Meds?
Diminishing Returns With Broader Use of ADHD Meds?

Medscape

time5 hours ago

  • Medscape

Diminishing Returns With Broader Use of ADHD Meds?

It's well known that medications used to treat attention-deficit hyperactivity disorder (ADHD) do more than address the core symptoms of inattention, hyperactivity, and impulsivity. They have also been associated with significant reductions in the risk for serious real-world outcomes such as self-harm, unintentional injury, car crashes, and crime. However, a large-scale Swedish study has found that the magnitude of associations between ADHD medication use and these real-world outcomes appears to have weakened, in parallel with rising prescription rates. 'The declining strength of the associations of ADHD medication and real-world outcomes could be attributed to the expansion of prescriptions to a broader group of individuals having fewer symptoms or impairments,' first author Lin Li, PhD, Karolinska Institutet, Stockholm, Sweden, and colleagues wrote. The findings were published online on June 25 in JAMA Psychiatry. Waning Real-World Impact? The rate of ADHD medication use has risen substantially in many countries over the past two decades. With treatment now reaching a broader population of individuals who may have less severe symptoms, an emerging question is whether there remains a meaningful reduction in real-world harm. To investigate, Li and colleagues analyzed health data from Swedish national registers for 247,420 individuals aged 4-64 years who were prescribed ADHD medications between 2006 and 2020. They employed a self-controlled case series design, which allowed individuals to serve as their own controls. Outcomes included rates of self-harm, unintentional injury, traffic crashes, and crime measured during medicated vs nonmedicated periods. Over the 14-year study period, ADHD medication use rose sharply in Sweden — from 0.6% to 2.8% in children and from 0.1% to 1.3% in adults. ADHD medication use was consistently linked to reduced risks for self-harm (incidence rate ratio [IRR] range, 0.77-0.85), unintentional injury (IRR range, 0.87-0.93), traffic crashes (IRR range, 0.71-0.87) and crime (IRR range, 0.73-0.84) across all analyzed time periods, age groups, and sexes. However, the magnitude of risk reduction for these real-world outcomes diminished significantly over time ( P < .01) and was not fully explained by the age and sex distribution of people taking ADHD medication. The study team noted that the strongest associations between ADHD medication and reduced risk for real-world outcomes were consistently observed in women during the earliest study period (2006-2010), a time when only the most severe ADHD cases in women were being diagnosed and treated. Over time, as more women were prescribed ADHD medication, the sex differences on the various real-world outcomes narrowed, investigators said. In an accompanying editorial in JAMA Psychiatry , Ryan S. Sultan, MD, Department of Psychiatry, College of Physicians and Surgeons, Columbia University and the New York State Psychiatric Institute, New York City, and colleagues said it's 'critically' important to remember that the purpose of ADHD treatment is not primarily to prevent arrests, car crashes, or self-harm crises but to improve patients' daily functioning and quality of life. 'The accumulation of evidence makes one thing clear: When used appropriately, ADHD medications can help affected people not just feel better but live safer, more productive lives. This message is important as many individuals with ADHD still do not receive medication as their first-line treatment, despite medications having the most robust evidence for ADHD,' the editorialists wrote.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store